English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Current guidelines around preclinical screening for drug-induced arrhythmias require the measurement of the potency of block of voltage-gated potassium channel subtype 11.1 (K v 11.1) as a surrogate for risk. A shortcoming of this approach is that the measured IC 50 of K v 11.1 block varies widely depending on the voltage protocol used in electrophysiological assays. In this study, we aimed to investigate the factors that contribute to these differences and to identify whether it is possible to make predictions about protocol-dependent block that might facilitate the comparison of potencies measured using different assays. Our data demonstrate that state preferential binding, together with drug-binding kinetics and trapping, is an important determinant of the protocol dependence of K v 11.1 block. We show for the first time that differences in IC 50 measured between protocols occurs in a predictable way, such that machine-learning algorithms trained using a selection of simple voltage protocols can indeed predict protocol-dependent potency. Furthermore, we also show that the preference of a drug for binding to the open versus the inactivated state of K v 11.1 can also be inferred from differences in IC 50 values measured between protocols. Our work therefore identifies how state preferential drug binding is a major determinant of the protocol dependence of IC 50 values measured in preclinical K v 11.1 assays. It also provides a novel method for quantifying the state dependence of K v 11.1 drug binding that will facilitate the development of more complete models of drug binding to K v 11.1 and improve our understanding of proarrhythmic risk associated with compounds that block K v 11.1.

molecular pharmacology

Protocol-Dependent Differences in IC<sub>50</sub> Values Measured in Human Ether-Á-Go-Go–Related Gene Assays Occur in a Predictable Way and Can Be Used to Quantify State Preference of Drug Binding

Protocol-Dependent Differences in IC50 Values Measured in Human Ether-Á-Go-Go–Related Gene Assays Occur in a Predictable Way and Can Be Used to Quantify State Preference of Drug Binding

Protocol-Dependent Differences in IC₅₀ Values Measured in Human Ether-Á-Go-Go–Related Gene Assays Occur in a Predictable Way and Can Be Used to Quantify State Preference of Drug Binding